Implantable Cardiac Alert System for Early Recognition of ST-Segment Elevation Myocardial Infarction

被引:24
|
作者
Gibson, C. Michael [1 ]
Holmes, David [2 ]
Mikdadi, Ghiath [3 ]
Presser, Dale [4 ]
Wohns, David [5 ]
Yee, Megan K. [1 ]
Kaplan, Andrew [6 ]
Ciuffo, Allen [7 ]
Eberly, Arthur L., III [8 ]
Iteld, Bruce [9 ]
Krucoff, Mitchell W. [10 ,11 ]
机构
[1] Harvard Med Sch, Div Cardiovasc Med, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA
[2] Mayo Clin, Dept Cardiovasc Med, Rochester, MN USA
[3] Heart Clin Hammond, Hammond, LA USA
[4] Innovat Med Res LLC, Covington, LA USA
[5] Frederick Meijer Heart & Vasc Inst, Div Cardiovasc Med, Spectrum Hlth, Grand Rapids, MI USA
[6] Banner Heart Hosp, Mesa, AZ USA
[7] Sentara Healthcare Norfolk, Norfolk, VA USA
[8] Greenville Hlth Syst, Div Cardiol, Dept Internal Med, Greenville, SC USA
[9] Louisiana Heart Ctr, Hammond, LA USA
[10] Duke Univ, Med Ctr, Durham, NC USA
[11] Duke Clin Res Inst, Durham, NC USA
关键词
acute coronary syndrome; implantable monitoring device; ST-segment elevation myocardial infarction; symptom-to-door time; TO-BALLOON TIME; EMERGENCY MEDICAL-SERVICES; INTRACARDIAC ELECTROGRAM; MORTALITY; ONSET; PREVALENCE; DELAY; INTERVENTION; ANGIOPLASTY; THROMBOSIS;
D O I
10.1016/j.jacc.2019.01.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Symptoms remain a poor prompt for acute coronary syndromes (ACS). Timely restoration of perfusion in ST-segment elevation myocardial infarction is associated with improved left ventricular function and survival. OBJECTIVES This report details the results of ALERTS (AngelMed for Early Recognition and Treatment of STEMI), a multicenter, randomized trial of an implantable cardiac monitor that alerts patients with rapidly progressive ST-segment deviation. METHODS High-risk ACS subjects (N = 907) were randomized to a control (alarms deactivated) or treatment group for 6 months, after which alarms were activated in all subjects. The primary safety endpoint was absence of system-related complications (>90%). The composite primary efficacy endpoint was cardiac/unexplained death, new Q-wave myocardial infarction, or detection to presentation time >2 h. RESULTS Safety was met with 96.7% freedom from system-related complications (n = 30). The efficacy endpoint for a confirmed occlusive event within 7 days was not significantly reduced in the treatment compared with control group (16 of 423 [3.8%] vs. 21 of 428 [4.9%], posterior probability = 0.786). Within a 90-day window, alarms significantly decreased detection to arrival time at a medical facility (51 min vs. 30.6 h; Pr [pt < pc] >0.999). In an expanded analysis using data after the randomized period, positive predictive value was higher (25.8% vs. 18.2%) and false positive rate significantly lower in the ALARMS ON group (0.164 vs. 0.678 false positives per patient-year; p < 0.001). CONCLUSIONS The implantable cardiac system detects early ST-segment deviation and alerts patients of a potential occlusive event. Although the trial did not meet its pre-specified primary efficacy endpoint, results suggest that the device may be beneficial among high-risk subjects in potentially identifying asymptomatic events. (AngelMed for Early Recognition and Treatment of STEMI [ALERTS]; NCT00781118) (C) 2019 by the American College of Cardiology Foundation.
引用
收藏
页码:1919 / 1927
页数:9
相关论文
共 50 条
  • [1] Early management of ST-segment elevation myocardial infarction
    Sura, AC
    Kelemen, MD
    CARDIOLOGY CLINICS, 2006, 24 (01) : 37 - +
  • [2] ST-segment elevation myocardial infarction
    Yerem Yeghiazarians
    Peter H. Stone
    Current Treatment Options in Cardiovascular Medicine, 2002, 4 (1) : 3 - 23
  • [3] ST-segment elevation myocardial infarction
    Birgit Vogel
    Bimmer E. Claessen
    Suzanne V. Arnold
    Danny Chan
    David J. Cohen
    Evangelos Giannitsis
    C. Michael Gibson
    Shinya Goto
    Hugo A. Katus
    Mathieu Kerneis
    Takeshi Kimura
    Vijay Kunadian
    Duane S. Pinto
    Hiroki Shiomi
    John A. Spertus
    P. Gabriel Steg
    Roxana Mehran
    Nature Reviews Disease Primers, 5
  • [4] ST-Segment Elevation Myocardial Infarction
    Younis, George A.
    TEXAS HEART INSTITUTE JOURNAL, 2022, 49 (05) : 111 - 111
  • [5] ST-segment elevation myocardial infarction
    Vogel, Birgit
    Claessen, Bimmer E.
    Arnold, Suzanne, V
    Chan, Danny
    Cohen, David J.
    Giannitsis, Evangelos
    Gibson, C. Michael
    Coto, Shinya
    Katus, Hugo A.
    Kerneis, Mathieu
    Kimura, Takeshi
    Kunadian, Vijay
    Pinto, Duane S.
    Shiomi, Hiroki
    Spertus, John A.
    Steg, P. Gabriel
    Mehran, Roxana
    NATURE REVIEWS DISEASE PRIMERS, 2019, 5 (1)
  • [7] Cardiac Arrest in Acute ST-Segment Elevation Myocardial Infarction
    Andreou, Andreas Y.
    TEXAS HEART INSTITUTE JOURNAL, 2022, 49 (05)
  • [8] Early usage of antiplatelet in ST-segment elevation myocardial infarction
    He, Haohui
    Zhou, Tao
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 326 : 43 - 43
  • [9] Anticoagulation for ST-Segment Elevation Myocardial Infarction
    Eikelboom, John W.
    Weitz, Jeffrey I.
    CIRCULATION, 2009, 119 (09) : 1186 - 1188
  • [10] The challenge of ST-segment elevation myocardial infarction
    Cohen, M.
    Roubin, G.
    Kuepper, F.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 (12) : 2079 - 2092